<p>Redhill Biopharma Ltd. will hold an Extraordinary General Meeting of Shareholders in Tel-Aviv, Israel, on March 5, 2026. Shareholders will vote on several proposals, including the approval of grants of restricted share units (RSUs) to the non-executive directors, to Dror Ben-Asher, the company’s Chief Executive Officer and Chairman of the Board of Directors, and to Rick D. Scruggs, the company’s Chief Commercial Officer and Director. Additionally, shareholders will consider a proposal to approve an increase in the company’s authorized share capital. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-000196), on January 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

RedHill Biopharma Ltd. Announces Date for Extraordinary General Meeting of Shareholders